Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common gout drug help heart failure patients breathe easier?

NCT ID NCT06130059

Recruiting now Symptom relief Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a low dose of colchicine, an anti-inflammatory drug, can improve exercise capacity in people with heart failure and chronic inflammation. Sixty participants will be randomly assigned to receive either colchicine or a placebo for three months. Researchers will measure changes in exercise tests, physical function, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Low dose colchicine (LoDoCo)
What this could lead to
If it works, this could point toward a new way to help people with heart failure feel less tired and move more easily.
What could go wrong
This is a small, early pilot study with only 60 people. The drug may not improve exercise capacity more than a placebo, and results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE INFLAMMATION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UT Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75235, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.